Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Woodline Partners LP

Woodline Partners LP increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 100.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,561,622 shares of the biopharmaceutical company's stock after acquiring an additional 783,466 shares during the period. Bristol-Myers Squibb comprises 0.6% of Woodline Partners LP's investment portfolio, making the stock its 24th biggest position. Woodline Partners LP owned approximately 0.08% of Bristol-Myers Squibb worth $88,325,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Bristol-Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after acquiring an additional 1,373,209 shares in the last quarter. Capital International Investors raised its position in Bristol-Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after purchasing an additional 3,218,865 shares in the last quarter. Geode Capital Management LLC raised its position in Bristol-Myers Squibb by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after purchasing an additional 1,187,231 shares in the last quarter. Norges Bank acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $1,989,525,000. Finally, Ameriprise Financial Inc. raised its position in Bristol-Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Analysts Set New Price Targets

BMY has been the topic of a number of analyst reports. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Jefferies Financial Group dropped their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Up 1.0%

Shares of BMY stock opened at $47.22 on Tuesday. The business's 50 day moving average is $52.80 and its two-hundred day moving average is $55.94. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market capitalization of $96.10 billion, a P/E ratio of -10.68, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period last year, the firm earned ($4.40) EPS. Equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.25%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.